Nelson Vergel
Founder, ExcelMale.com
The U.S. Food and Drug Administration today approved Jatenzo (testosterone undecanoate), an oral testosterone capsule to treat men with certain forms of hypogonadism. These men have low testosterone levels due to specific medical conditions, such as genetic disorders like Klinefelter syndrome or tumors that have damaged the pituitary gland. Jatenzo should not be used to treat men with “age-related hypogonadism,” in which testosterone levels decline due to aging, even if these men have symptoms that appear to be related to low testosterone. Jatenzo’s benefits do not outweigh its risks for that use.
This oral version of testosterone undecanoate has been available in Canada for years. It has a short half-life.
https://www.fda.gov/downloads/Advis...iveHealthDrugsAdvisoryCommittee/UCM591416.pdf
This oral version of testosterone undecanoate has been available in Canada for years. It has a short half-life.
https://www.fda.gov/downloads/Advis...iveHealthDrugsAdvisoryCommittee/UCM591416.pdf